H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis

Launched by TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL · May 14, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with stage IIIa primary liver cancer who also have a blockage in their portal vein, known as portal vein thrombosis. The study will compare the safety and effectiveness of a special type of virus injection, combined with a treatment called TACE (transarterial chemoembolization), to see if this combination can help improve outcomes for these patients. This is an important step as it may provide a new, reliable treatment option for people facing this serious condition.

To participate in the trial, candidates must be between 18 and 75 years old, have confirmed stage IIIa primary liver cancer, and meet certain health criteria, such as having good overall physical condition and expected survival of at least three months. Participants will receive the study treatment and will need to agree to follow-up visits and tests. It’s also important for women of childbearing age and their male partners to use effective contraception during the study to avoid pregnancy. This trial is currently not recruiting participants, but it aims to offer valuable insights into potential treatments for liver cancer and help guide future care for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years and ≤ 75 years, regardless of gender;
• • 2. Patients with stage IIIa primary liver cancer diagnosed by histology or imaging;
• • 3. ECOG physical status score of 0-1;
• • 4. Expected survival time ≥ 3 months;
• 5. Received no liver protective and supportive treatment within two weeks before enrollment, and met the following conditions:
• • White blood cell count ≥3.0×109/L, neutrophil absolute value ≥3.0×109/L, platelet count ≥50×109/L, hemoglobin \> 100g/L;
• • INR≤1.5 and APTT≤1.5 upper limit of normal or partial prothrombin time (PTT) ≤1.5 upper limit of normal;
• • Total bilirubin (TBIL) ≤2.5 times the upper limit of normal value; ALT and AST≤5 times the upper limit of normal value; Serum creatinine ≤1.5 times the upper limit of normal value;
• • Creatinine clearance ≥50ml/min.
• • 6. Voluntary participation in this study and signing of the informed consent form;
• • 7. Female patients of childbearing age or male patients whose sexual partners are women of childbearing age are required to use effective contraception throughout the treatment period and for 6 months after the last dose.
• Exclusion Criteria:
• • 1. Pregnant or lactating women, men or women who do not wish to use effective contraception;
• • 2. Patients who have received previous treatment with lysoviruses (e.g., T-VEC), interventional therapy, or TACE;
• • 3. Those who are being treated with antiviral drugs;
• • 4. having received any other experimental drug, antimicrobial drug, or participated in another interventional clinical trial within 4 weeks prior to enrollment
• • 5. Those with a known allergy to the study drug or its active ingredient, or a history of allergy to similar biological agents
• • 6. Evidence of Child-Pugh C hepatic function or hepatocellular dysregulation, including those with refractory ascites, ruptured esophageal or gastric variceal bleeding, and hepatic encephalopathy
• • 7. presence of a history of immunodeficiency or autoimmune disease or long-term systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to enrollment
• • 8. With any unstable systemic disease, including but not limited to: severe infection, hypertensive patients, uncontrolled diabetes mellitus, unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia, abnormal mental status or active cerebral hemorrhage, myocardial infarction, congestive heart failure, severe arrhythmias requiring drug therapy, renal or metabolic disease, severe hepatic dysfunction (including severe jaundice, hepatic encephalopathy, refractory ascites or hepatorenal syndrome), multiple organ failure with renal dysfunction;
• • 9. Previous or concurrent other malignancies;
• • 10. Combined medical contraindications that preclude any contrast-enhanced imaging (CT or MRI);
• • 11. Other conditions that, in the judgment of the investigator, make the patient unsuitable for participation in this study.